15 September 2022 | Other

Pfizer begins final phase of mRNA-based flu vaccine trials

Pfizer Inc. has begun conducting the final phase of a flu vaccine trial in the United States. The final phase of the trial will involve 25,000 patients. This is one of the first such trials for an mRNA-based flu vaccine.

Pfizer Inc reported that first participants have already received the vaccine shot. Its manufacture is based on the same technology as the common COVID-19 vaccine. The technology was developed jointly with the German organization BioNTech SE.

Between 12,000 and 52,000 people die of influenza in the U.S. each year. But vaccines use strains that require annual replacement before flu season - circulating viruses are constantly evolving.

With the advent of mRNA technology, the ability to change strains in vaccines more quickly has been achieved. Pfizer expects this to provide more accurate strain matching in the future.

Company MarketCheese
Brent sell
Period: 17.07.2025 Expectation: 150 pips
OPEC's gloomy forecast drags Brent crude prices lower
Today at 08:53 AM 4
Period: 17.07.2025 Expectation: 26000 pips
Institutional investor demand could push ETHUSD to 3,000
Yesterday at 10:38 AM 34
Period: 16.07.2025 Expectation: 2000 pips
USDJPY prepares to retest 148 Level
Yesterday at 08:19 AM 38
Period: 16.07.2025 Expectation: 900 pips
NVIDIA shares rise amid global AI infrastructure investments
09 July 2025 66
Period: 15.07.2025 Expectation: 800 pips
Breaking downtrend could push USDCAD to 1.375
09 July 2025 43
Period: 14.07.2025 Expectation: 1600 pips
Upcoming “Crypto Week” to boost bitcoin prices
08 July 2025 109
Go to forecasts